NEW YORK — For a project born in a cauldron of controversy three years ago, the “GP-write” effort to design and build synthetic genomes — and, as long as researchers were going to all that trouble, improve on nature’s versions — has evolved from the early hopes, and even hubris, of 2016 into something a little less in your face. Judging by its just-ended annual meeting, GP (for “genome project”)-write is now less a “project,” into which some critics read nefarious intent, and more a warm, fuzzy “community.”

“We still have a vision of people coming together around a single project” analogous to the human genome project, said Jef Boeke, director of the Institute for Systems Genetics at New York University Langone Health and co-founder of GP-write. But “we have shifted from a top-down approach to more of a loose federation of programs. But that doesn’t rule out the possibility of returning to a centralized program in the future.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy